WALEED KHALIL: Open Payments
NPI 1700879723 · NEWBURGH, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$660 in 35 payments from 11 companies in 2025. Trend: 2023 $696 · 2024 $1,114 · 2025 $660
Food & beverage: $660
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $236 |
| GENZYME CORPORATION | 4 | $125 |
| PFIZER INC. | 5 | $79 |
| Intercept Pharmaceuticals, Inc. | 2 | $43 |
| Ardelyx, Inc. | 1 | $34 |
| Madrigal Pharmaceuticals | 2 | $30 |
| Janssen Biotech, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $24 |
| Olympus America Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
Products named: XIFAXAN, DUPIXENT, XELJANZ, OCALIVA, IBSRELA, REZDIFFRA, TREMFYA, CREON.
Industry payments across NY — which companies pay providers there.
